Brigitte Vanle

Brigitte Vanle

Auto-generated profile, based on publicly available information

Brigitte Vanle

Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, The University of Iowa, Iowa City, IA, 52242, United States

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Harvard Review of Psychiatry
Verified
Journal Article
Closed access
WIWaguih William IsHak
Waguih William IsHak
RWRaymond Y. Wen
Raymond Y. Wen
LNLancer Naghdechi
Lancer Naghdechi
BVBrigitte Vanle
Brigitte Vanle
JDJonathan Dang
Jonathan Dang
CLCharles Louy
Charles Louy
Background: Pain comorbid with depression is frequently encountered in clinical settings and often leads to significant impaired functioning. Given the complexity of comorbidities, it is important to address both pain and depressive symptoms when evaluating treatment options. Aim: To review studies addressing pain comorbid with depression, and to report the impact of current treatments. Method: A systematic search of the literature databases was conducted according to predefined criteria. Two authors independently conducted a focused analysis of the full-text articles and reached a consensus on 28 articles to be included in this review. Results: Overall, studies suggested that pain and depression are highly intertwined and may co-exacerbate physical and psychological symptoms. These symptoms could lead to poor physical functional outcomes and longer duration of symptoms. An important biochemical basis for pain and depression focuses on serotonergic and norepinephrine systems, which is evident in the pain-ameliorating properties of serotonergic and norepinephrine antidepressants. Alternative pharmacotherapies such as ketamine and cannabinoids appear to be safe and effective options for improving depressive symptoms and ameliorating pain. In addition, cognitive-behavioral therapy may be a promising tool in the management of chronic pain and depression. Conclusion: The majority of the literature indicates that patients with pain and depression experience reduced physical, mental, and social functioning as opposed to patients with only depression or only pain. In addition, ketamine, psychotropic, and cognitive-behavioral therapies present promising options for treating both pain and depression.

1 November 2017 in Therapeutic Advances in Psychopharmacology
Verified
Journal Article
Open access
SCSteven S. Clevenger
Steven S. Clevenger
DMDevvrat Malhotra
Devvrat Malhotra
JDJonathan Dang
Jonathan Dang
BVBrigitte Vanle
Brigitte Vanle
WIWaguih William IsHak
Waguih William IsHak
The objective of this review was to evaluate the efficacy of selective serotonin reuptake inhibitors (SSRIs) and SSRIs compared with other treatment modalities in preventing relapse after an episode of major depressive disorder (MDD). An Ovid MEDLINE and PsycINFO search (from 1987 to August 2017) was conducted using the following terms: selective serotonin reuptake inhibitors, antidepressants, depression, prevention, prophylaxis, relapse and MDD. Using predefined criteria, two authors independently selected and reached consensus on the included studies. Sixteen articles met the criteria: 10 compared the relapse rate of selective SSRIs with placebo or other SSRIs; one discussed the effectiveness of SSRIs plus psychotherapy, two compared SSRI versus tricyclic antidepressants (TCAs), two were mainly composed of TCAs plus psychotherapy, and one compared SSRIs and serotonin norepinephrine reuptake inhibitors (SNRIs). According to the included studies, the relapse risk in adults was lower when SSRIs were combined with psychotherapy. Results comparing SSRIs and SNRIs were inconclusive. TCAs may be equally as effective as SSRIs. Atypical antidepressants (mirtazapine and St John’s Wort) had no significant difference in efficacy and remission rates compared with SSRIs. Escitalopram appeared to fare better in efficacy than other SSRIs, owing to a higher prophylactic efficacy and lower side effects; however, according to the current data, this difference was not significant. To conclude, this review provides evidence that continuing SSRIs for 1 year reduces risk of MDD and relapse. Furthermore, the combination of SSRIs and cognitive behavioural therapy may effectively reduce relapse. Escitalopram appeared to yield better results and fewer side effects than did other SSRIs or SNRIs. The effectiveness in reducing relapse of SSRIs was similar to that of TCAs and atypical antidepressants.

15 June 2018 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
BVBrigitte Vanle
Brigitte Vanle
WOWilliam Olcott
William Olcott
JJJaime Jimenez
Jaime Jimenez
LBLuma Bashmi
Luma Bashmi
IDItai Danovitch
Itai Danovitch
WIWaguih William IsHak
Waguih William IsHak
Among patients with Parkinson’s disease (PD), depression is prevalent and disabling, impacting both health outcomes and quality of life. There is a critical need for alternative pharmacological methods to treat PD depression, as mainstream antidepressant drugs are largely ineffective in this population. Currently, there are no recommendations for the optimal treatment of PD neuropsychiatric symptoms. Given the dual antidepressant and anti-dyskinetic effects of ketamine and other N-methyl-D-aspartate (NMDA) antagonists for PD, this review aims to examine the current evidence of NMDA antagonists for treating neuropsychiatric symptoms, including memantine, amantadine, ketamine, dizoclopine, and d-cycloserine. A comprehensive literature search was conducted using the PubMed database. We also searched the following databases up to March 1, 2018: Ovid MEDLINE, PsycINFO, CINAHL, Google Scholar, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews. The following keywords were used: NMDA antagonist and Parkinson’s disease. Two authors independently reviewed the articles identified from the search using specific selection criteria, focusing on studies of mood, psychiatric condition, depression, cognition, and quality of life, and the consensus was reached on the 20 studies included. There is a preliminary evidence that NMDA antagonists may modulate psychiatric symptoms in PD. However, current evidence of psychiatric symptom-modifying effects is inconclusive and requires that further trials be conducted in PD. The repurposing of old NMDA antagonists, such as ketamine for depression and newer therapies, such as rapastinel, suggests that there is an emerging place for modulating the glutamatergic system for treating non-motor symptoms in PD.

1 January 2014 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
JDJonathan A Doorn
Jonathan A Doorn
VFVirginia R. Florang
Virginia R. Florang
JSJosephine H. Schamp
Josephine H. Schamp
BVBrigitte C. Vanle
Brigitte C. Vanle

1 September 2018 in Environmental Toxicology and Pharmacology
Verified
Journal Article
Closed access
EREric A. Rodriguez
Eric A. Rodriguez
BVBrigitte C. Vanle
Brigitte C. Vanle
JDJonathan A. Doorn
Jonathan A. Doorn
HLHans-Joachim Lehmler
Hans-Joachim Lehmler
LRLarry W. Robertson
Larry W. Robertson
MDMichael W. Duffel
Michael W. Duffel

1 February 2018 in Toxicology
Verified
Journal Article
Closed access
SESabah H. Enayah
Sabah H. Enayah
BVBrigitte C. Vanle
Brigitte C. Vanle
LFLaurence J. Fuortes
Laurence J. Fuortes
JDJonathan A. Doorn
Jonathan A. Doorn
GLGabriele Ludewig
Gabriele Ludewig